Edoxaban treatment in atrial fibrillation in routine clinical care: One‐year outcomes of the prospective observational ETNA‐AF study in South Korean patients

Abstract

BackgroundThe real‐world outcomes of edoxaban treatment in patients with atrial fibrillation (AF) were analyzed in the ETNA‐AF (Edoxaban Treatment in Routine Clinical Practice) study involving data from multiple regional registries. This report addresses effectiveness and safety of edoxaban in the Korean ETNA‐AF population.MethodsOne‐year data from 1887 Korean ETNA‐AF participants were analyzed according to edoxaban dose and patient age and compared with results of other ETNA‐AF registries.ResultsApproximately 70% of patients received the recommended doses of edoxaban (60 mg/30 mg); non‐recommended 60 mg and 30 mg doses were prescribed to 9.6% and 19.8% of the patients, respectively. The proportions of reference age (<65 years), youngest‐old (65–74 years) and middle‐old/oldest‐old (≥75 years) groups were 21.4%, 40.2%, and 38.4%, respectively. Incidence of major or clinically relevant nonmajor bleeding was similar within dose (0.57%–1.71%) and age subgroups (1.26%–1.63%). Incidence of net clinical outcome, a composite of stroke, systemic embolic event, major bleeding, and all‐cause mortality, was also comparable among dose subgroups (1.14%–3.10%) and age subgroups (2.28%–2.78%). The percentage of Korean patients receiving non‐recommended 30 mg (19.8%) was over twice that of the European population (8.4%). However, the clinical outcomes were generally similar among different populations included in the ETNA‐AF study.ConclusionsThe outcomes in the Korean ETNA‐AF population are like those in the global ETNA‐AF population, with overall low event rates of stroke, major bleeding and all‐cause mortality across age and dose subgroups. Edoxaban can be used effectively and safely in specific populations of Korean AF patients, including the elderly.